Maureen Rischmueller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/11120846/publications.pdf

Version: 2024-02-01

56 papers	3,214 citations	172457 29 h-index	168389 53 g-index
57 all docs	57 docs citations	57 times ranked	4335 citing authors

#	Article	IF	Citations
1	<scp>47XXY</scp> and <scp>47XXX</scp> in Scleroderma and Myositis. ACR Open Rheumatology, 2022, 4, 528-533.	2.1	8
2	Characterization and outcomes of 414 patients with primary SS who developed haematological malignancies. Rheumatology, 2022, 62, 243-255.	1.9	12
3	Upadacitinib monotherapy versus methotrexate monotherapy in methotrexate-naÃ¯ve Japanese patients with rheumatoid arthritis: a sub-analysis of the Phase 3 SELECT-EARLY study. Modern Rheumatology, 2021, 31, 534-542.	1.8	6
4	Influence of the age at diagnosis in the disease expression of primary SjÃ¶gren syndrome. Analysis of 12,753 patients from the SjÃ¶gren Big Data Consortium. Clinical and Experimental Rheumatology, 2021, 39, 166-174.	0.8	12
5	Influence of the age at diagnosis in the disease expression of primary SjÃ¶gren syndrome. Analysis of 12,753 patients from the SjÃ¶gren Big Data Consortium.. Clinical and Experimental Rheumatology, 2021, 39 Suppl 133, 166-174.	0.8	0
6	Epidemiological profile and northâ€“south gradient driving baseline systemic involvement of primary SjÃ¶grenâ€™s syndrome. Rheumatology, 2020, 59, 2350-2359.	1.9	54
7	Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis. New England Journal of Medicine, 2020, 383, 1511-1521.	27.0	151
8	Increased Serum IgG4 Associates with Asthma and Tissue Eosinophilia in Chronic Rhinosinusitis Patients. Pathogens, 2020, 9, 828.	2.8	2
9	Efficacy and Safety of Upadacitinib Monotherapy in Methotrexateâ€Naive Patients With Moderatelyâ€toâ€Severely Active Rheumatoid Arthritis (SELECTâ€EARLY): A Multicenter, Multiâ€Country, Randomized, Doubleâ€Blind, Active Comparatorâ€“Controlled Trial. Arthritis and Rheumatology, 2020, 72, 1607-1620.	5.6	126
10	Lymphoma Driver Mutations in the Pathogenic Evolution of an Iconic Human Autoantibody. Cell, 2020, 180, 878-894.e19.	28.9	82
11	Primary SjÃ¶gren's syndrome in South Australia. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 57-63.	0.8	2
12	When B cells break bad: development of pathogenic B cells in SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 271-282.	0.8	4
13	Systemic phenotype related to primary SjÃ¶gren's syndrome in 279 patients carrying isolated anti-La/SSB antibodies. Clinical and Experimental Rheumatology, 2020, 38 Suppl 126, 85-94.	0.8	2
14	Serum and urinary macrophage migration inhibitory factor (MIF) in primary SjÃ¶gren's syndrome. Joint Bone Spine, 2019, 86, 393-395.	1.6	4
15	Serum soluble Fas and Fas ligand (FasL) in primary SjÃ¶gren's syndrome. Clinical and Experimental Rheumatology, 2019, 37 Suppl 118, 254-256.	0.8	1
16	Pomalidomide in Patients with Interstitial Lung Disease due to Systemic Sclerosis: A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Study. Journal of Rheumatology, 2018, 45, 405-410.	2.0	31
17	Influence of geolocation and ethnicity on the phenotypic expression of primary SjÃ¶gren's syndrome at diagnosis in 8310 patients: a cross-sectional study from the Big Data SjÃ¶gren Project Consortium. Annals of the Rheumatic Diseases, 2017, 76, 1042-1050.	0.9	132
18	Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet, The, 2017, 390, 457-468.	13.7	360

#	Article	IF	Citations
19	Brief Report: Rare X Chromosome Abnormalities in Systemic Lupus Erythematosus and SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2017, 69, 2187-2192.	5.6	35
20	Tertiary lymphoid organs in recalcitrant chronic rhinosinusitis. Journal of Allergy and Clinical Immunology, 2017, 139, 1371-1373.e6.	2.9	21
21	Identification of a SjÃ¶gren's syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. PLoS Genetics, 2017, 13, e1006820.	3.5	60
22	X Chromosome Dose and Sex Bias in Autoimmune Diseases: Increased Prevalence of 47,XXX in Systemic Lupus Erythematosus and SjÃ¶gren's Syndrome. Arthritis and Rheumatology, 2016, 68, 1290-1300.	5.6	114
23	Active Foot Synovitis in Patients With Rheumatoid Arthritis: Unstable Remission Status, Radiographic Progression, and Worse Functional Outcomes in Patients With Foot Synovitis in Apparent Remission. Arthritis Care and Research, 2016, 68, 1616-1623.	3.4	31
24	PTPN22R620W minor allele is a genetic risk factor for giant cell arteritis. RMD Open, 2016, 2, e000246.	3.8	9
25	Klinefelter's syndrome (47,XXY) is in excess among men with SjÃ¶gren's syndrome. Clinical Immunology, 2016, 168, 25-29.	3.2	68
26	Primary SjÃ¶gren's syndrome. Best Practice and Research in Clinical Rheumatology, 2016, 30, 189-220.	3.3	88
27	The IRF5â€“TNPO3 association with systemic lupus erythematosus has two components that other autoimmune disorders variably share. Human Molecular Genetics, 2015, 24, 582-596.	2.9	74
28	Fish oil in recent onset rheumatoid arthritis: a randomised, double-blind controlled trial within algorithm-based drug use. Annals of the Rheumatic Diseases, 2015, 74, 89-95.	0.9	129
29	Variants at multiple loci implicated in both innate and adaptive immune responses are associated with SjÃ¶gren's syndrome. Nature Genetics, 2013, 45, 1284-1292.	21.4	427
30	Epistasis with HLA DR3 implicates the P2X7 receptor in the pathogenesis of primary SjÃ¶gren's syndrome. Arthritis Research and Therapy, 2013, 15, R71.	3.5	17
31	Response to: The interaction of Sjogrenâ€™s syndrome, gastroesophageal reflux and sleep by Tufik et al.. Sleep Medicine, 2013, 14, 222-223.	1.6	0
32	No Association between FCÎ³R3B Copy Number Variation and Susceptibility to Biopsy-Proven Giant Cell Arteritis. Arthritis, 2013, 2013, 1-4.	2.0	1
33	Susceptibility for Lupus Nephritis by Low Copy Number of theFCGR3BGene Is Linked to Increased Levels of Pathogenic Autoantibodies. Autoimmune Diseases, 2013, 2013, 1-6.	0.6	6
34	Low Copy Number of the Fc-Î³ Receptor 3B Gene FCGR3B Is a Risk Factor for Primary SjÃ¶grenâ€™s Syndrome. Journal of Rheumatology, 2012, 39, 2142-2147.	2.0	33
35	Sleep disordered breathing in patients with primary SjÃ¶grenâ€™s syndrome: A group controlled study. Sleep Medicine, 2012, 13, 1066-1070.	1.6	42
36	Low copy number of the FCGR3B gene and rheumatoid arthritis: a case-control study and meta-analysis. Arthritis Research and Therapy, 2012, 14, R28.	3.5	34

#	Article	IF	Citations
37	Active foot synovitis in patients with rheumatoid arthritis: Applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement. Arthritis and Rheumatism, 2012, 64, 1316-1322.	6.7	45
38	Activation of the Alternative NFÎºB Pathway Improves Disease Symptoms in a Model of Sjogren's Syndrome. PLoS ONE, 2011, 6, e28727.	2.5	26
39	Mortality in Patients with Biopsy-proven Giant Cell Arteritis: A South Australian Population-based Study. Journal of Rheumatology, 2011, 38, 2215-2217.	2.0	47
40	SjÃ¶grenâ€™s Syndrome in Australia: Clinical Practice and Research. , 2011, , 423-424.		0
41	Risk of cancer in patients with biopsy-proven giant cell arteritis. Rheumatology, 2010, 49, 756-759.	1.9	23
42	Mild autonomic dysfunction in primary SjÃ¶gren's syndrome: a controlled study. Arthritis Research and Therapy, 2008, 10, R31.	3.5	36
43	Upper Airway Surface Tension but not Upper Airway Collapsibility is Elevated in Primary SjÃ¶gren's Syndrome. Sleep, 2008, 31, 367-374.	1.1	27
44	Response-Driven Combination Therapy with Conventional Disease-Modifying Antirheumatic Drugs Can Achieve High Response Rates in Early Rheumatoid Arthritis with Minimal Glucocorticoid and Nonsteroidal Anti-Inflammatory Drug Use. Seminars in Arthritis and Rheumatism, 2007, 37, 99-111.	3.4	63
45	Influence ofCTLA4 haplotypes on susceptibility and some extraglandular manifestations in primary SjÃ¶gren's syndrome. Arthritis and Rheumatism, 2006, 54, 2434-2440.	6.7	56
46	Neutralization of Muscarinic Receptor Autoantibodies by Intravenous Immunoglobulin in SjÃ¶gren Syndrome. Human Immunology, 2005, 66, 411-416.	2.4	36
47	Muscarinic receptor autoantibodies in SjÃ¶grenâ€™s syndrome. , 2004, , 233-239.		0
48	Humoral immunity to Ro52 is not associated with the Ro52 9571 C/T polymorphism in Australian patients with primary SjÃ¶gren's syndrome. Arthritis and Rheumatism, 2003, 48, 3293-3294.	6.7	1
49	Increased severity of lower urinary tract symptoms and daytime somnolence in primary SjÃ¶gren's syndrome. Journal of Rheumatology, 2003, 30, 2406-12.	2.0	42
50	Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in SjÃ¶gren's syndrome. Arthritis and Rheumatism, 2000, 43, 1647-1654.	6.7	235
51	Determinant spreading: lessons from animal models and human disease. Immunological Reviews, 1998, 164, 209-229.	6.0	131
52	Human leukocyte antigen phenotype imposes complex constraints on the antigen-specific cytotoxic T lymphocyte repertoire. European Journal of Immunology, 1997, 27, 178-182.	2.9	37
53	Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. European Journal of Immunology, 1997, 27, 1726-1736.	2.9	161
54	Nonprecipitating Anti-La(SS-B) Autoantibodies in Primary SjÃ¶gren's Syndrome. Clinical Immunology and Immunopathology, 1996, 79, 314-318.	2.0	26

#	Article	IF	Citations
55	Rapid and sensitive detection of anti-ro (SS-A) antibodies by indirect immunofluorescence of 60kDa Ro HEp-2 transfectants. Pathology, 1996, 28, 54-57.	0.6	25
56	How Does Autoimmunity to La and Ro Initiate and Spread?. Autoimmunity, 1994, 18, 87-92.	2.6	18